Nucleic acid-controlled catalytic rnas for trigger-responsive regulation
US-2024425855-A1 · Dec 26, 2024 · US
Heptamer-type small guide nucleic acids inducing apoptosis of human leukemia cells
US9617538B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9617538-B2 |
| Application number | US-201214241580-A |
| Country | US |
| Kind code | B2 |
| Filing date | Aug 24, 2012 |
| Priority date | Aug 29, 2011 |
| Publication date | Apr 11, 2017 |
| Grant date | Apr 11, 2017 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
There is provided a heptamer-type small guide nucleic acid that comprises any of the 7-base sequences of SEQ ID NOS: 1 to 15, and induces apoptosis of human leukemia cells. A leukemia therapeutic agent containing the heptamer-type small guide nucleic acid as an active ingredient is also provided. The novel heptamer-type sg nucleic acid can induce apoptosis of human leukemia cells.
First claim
Opening claim text (preview).
The invention claimed is: 1. A leukemia therapeutic agent, which comprises one or more of a small guide RNA consisting of a sequence selected from SEQ ID NOS: 1, 2, 3, 4, 7, 8, 10, 11, 12, 13 or 15 as an active ingredient, wherein one or more of the small guide RNA is phosphorylated at the 5′ and 3′ ends, and is 2′-O-methylated. 2. A composition comprising one or more of a small guide RNA consisting of a sequence selected from SEQ ID NOS: 1, 2, 3, 4, 7, 8, 10, 11, 12, 13 or 15 and a pharmaceutically acceptable carrier, wherein one or more of the small guide RNA is phosphorylated at the 5′ and 3′ ends, and is 2′-O-methylated.
Assignees
Inventors
Classifications
Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links · CPC title
- C12N15/113Primary
Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; {Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing (when used in plants C12N15/8218)} · CPC title
specific for leukemia · CPC title
catalytic nucleic acids, e.g. ribozymes · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9617538B2 cover?
- There is provided a heptamer-type small guide nucleic acid that comprises any of the 7-base sequences of SEQ ID NOS: 1 to 15, and induces apoptosis of human leukemia cells. A leukemia therapeutic agent containing the heptamer-type small guide nucleic acid as an active ingredient is also provided. The novel heptamer-type sg nucleic acid can induce apoptosis of human leukemia cells.
- Who is the assignee on this patent?
- Nashimoto Masayuki, TAKAHASHI Masuhiro, NARITA Miwako, and 4 more
- What technology area does this patent fall under?
- Primary CPC classification C12N15/113. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Apr 11 2017 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).